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VALIDATION OF AN ORIGINAL ETP-BASED APC RESISTANCE ASSAY FOR THE EVALUATION 
OF PROTHROMBOTIC STATES
BACKGROUND
v The activated protein C resistance assay based on the endogenous thrombin
potential (ETP-based APCr assay) is recommended in guidance from medicines
regulatory authorities (e.g. EMA and FDA) for the investigation of steroid
contraceptives.1
v The results are usually “normalized” with a reference plasma to provide the
“normalized APC sensitivity ratio” (nAPCsr).2
v However, the methods described in the literature are home-made and mostly
without standardization of the method, the reagents, the reference plasma and the
quality controls.
METHOD
v Three quality controls (QCs) representing plasmas with diﬀerent levels of
coagulation and one reference plasma (Ref plasma) were used.
v The method targets a 90% inhibition of the ETP in a pool of plasma from healthy
donors (10 men and 10 women not using hormonal contraception, with no
coagulation abnormalities [i.e. FV Leiden nor G20210A mutation carrier)] in
presence of APC compared to the same condition in absence of APC. [▶ Figure 1]
§ Inhibition % = 100% - !"#$%& '() (+(,)!"#$%& '() (.(,)
v As the pool of healthy donors is not produced at large scale, specific algorithms are
applied to the commercial reference plasma to correlate with the pool.
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RESULTS
v Limits of acceptability of QCs and Ref plasma [▶ Table 1] were defined as
§ the mean of results obtained in the entire study (N=24) ± 2*SD
§ SD = the highest CV of the accuracy study * the mean of the entire accuracy
study
v Intra-run (into a same plate) and inter-run (between plates) repeatability passed the 
acceptance criteria : <10% of standard deviation. [▶ Table 2]
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AIM
To validate the analytical procedure of an ETP-based APCr assay according to the
regulatory standard ICHQ2R1 and CLSI guidelines.3
CONCLUSION
This study is the first describing the validation of ETP-based APCr assay according
to regulatory standards.
It provides the stakeholders, the regulatory bodies and the physicians with a
reproducible, sensitive and validated assay.
This will allow study-to-study comparison as well as perspectives for the
establishment of specific thresholds to reflect the prothrombotic state in the
individual patient.
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Figure 1 : Thrombin generation in absence of APC (blue curve)
and in presence of APC (red curve).
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QC high  (hypercoagulable) 12 ± 10%
Ref plasma 89 ± 6%
v The assay demonstrated a curvilinear dose-response to protein S and APC
concentrations (R2>0.99). [▶ Figure 2 and▶ figure 3]
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Non-linear regression:
§ one-phase association – least squares fit.
§ y = -27.45 + (94.02 +27.45)*(1 - exp (-0.04654*x))
§ R2 = 0.9981
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Figure 2: Inhibition percentage depending on a
protein S deficiency. Vertical dotted line
represents the limit of detection of the STA®-
Staclot® protein S kit.
v Analysis of plasma samples from 50 healthy individuals (22 women not taking
combined oral contraceptive (COC) and 28 men, no FV Leiden carrier) confirmed
the validity of the tests [acceptance criteria: mean = 90% (± 2,5%)] with a mean
inhibition percentage of 89%.
v Investigations in women taking COC confirmed the good sensitivity of the assay.
[▶ Figure 4]
Non-linear regression:
§ one-phase association – least squares fit.
§ y = -0.3374 + (91.03 +0.3374)*(1 - exp (-0.01025*x))
§ R2 = 0.9962
Figure 3: Inhibition percentage depending on
concentration of spiked APC. Horizontal dotted line
represents 90% inhibition.
Figure 4: Inhibition percentage of healthy individuals
(blue) and women using COC (red). The dotted green
line represents 90% inhibition.
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v Intermediate precision passed the acceptance criteria : standard deviation <10% and 
no significant diﬀerence between operators. [▶ Table 3]
Table 1 : Limits of acceptability (mean ±
2*SD) of QCs and Ref plasma.
Intra-run 
variability 
[SD]  
Inter-run 
variability 
[SD]
QC low (hypocoagulable) 0% 0%
QC intermediate
(intermediate coagulable) 1% 7%
QC high  (hypercoagulable) 3% 4%
Reference plasma 0% 3%
Table 2 : Intra- and inter-run
repeatability (expressed in SD).
Intra-run repeatability was
based on 5 measurements of the
Ref plasma and QCs and inter-
run repeatability was based on 10
runs measuring the Ref plasma
and QCs, performed by the same
operator.
Operator 
1  [SD]
Operator  
2 [SD]
Operator  
3 [SD] p-value
QC low (hypocoagulable) 0% 0% 0% 0.8503
QC intermediate
(intermediate coagulable) 4% 5% 2% 0.6969
QC high  (hypercoagulable) 3% 4% 0% 0.8253
Reference plasma 2% 2% 1% 0.9459
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Table 3 : Intermediate precision (expressed in SD and p-value) based on 3 runs measuring
the ref plasma and QCs and performed by 3 different operators.
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